Evaluation of aprepitant and fosaprepitant in pediatric patients.

Yoshimasa SaitoTadashi KumamotoTakamichi ArimaNami ShirakawaSae IshimaruTomoko SonodaMiho NakajimaMasanaka SugiyamaAyumu ArakawaHironobu HashimotoYoshinori MakinoChitose OgawaMasakazu Yamaguchi

Published in: Pediatrics international : official journal of the Japan Pediatric Society (2019)

Aprepitant and fosaprepitant were safely used and may be equally useful for pediatric patients receiving highly emetogenic chemotherapy. CR rate may be associated with patient age.

Keyphrases

chemotherapy induced
case report
young adults